Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Migralex is a specialty pharmaceutical company focused on the development and commercialization of over-the-counter treatments for migraine and tension-type headaches. The company's flagship product, Migralex, is a unique formulation that combines aspirin with magnesium oxide to facilitate rapid absorption and reduce gastrointestinal irritation. Founded by Dr. Alexander Mauskop, a renowned neurologist and director of the New York Headache Center, the company aims to provide patients with a fast-acting alternative to traditional oral pain relievers. Migralex is designed to offer the potency of prescription-level relief in an accessible, non-prescription format, specifically targeting the physiological mechanisms of acute migraine attacks.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Migralex.